Office of Public Sector Information
Section 1.
1(1)The members of the Advisory Council, of whom there shall be not less than twenty, shall be appointed by the Secretary of State after consultation with such organisations as he considers appropriate, and shall include—
(a)in relation to each of the activities specified in sub-paragraph (2) below, at least one person appearing to the Secretary of State to have wide and recent experience of that activity; and
(b)persons appearing to the Secretary of State to have wide and recent experience of social problems connected with the misuse of drugs.
(2)The activities referred to in sub-paragraph (1)(a) above are—
(a)the practice of medicine (other than veterinary medicine);
(b)the practice of dentistry;
(c)the practice of veterinary medicine;
(d)the practice of pharmacy;
(e)the pharmaceutical industry;
(f)chemistry other than pharmaceutical chemistry.
(3)The Secretary of State shall appoint one of the members of the Advisory Council to be chairman of the Council.
2The Advisory Council may appoint committees, which may consist in part of persons who are not members of the Council, to consider and report to the Council on any matter referred to them by the Council.
3At meetings of the Advisory Council the quorum shall be seven, and subject to that the Council may determine their own procedure.
4The Secretary of State may pay to the members of the Advisory Council such remuneration (if any) and such travelling and other allowances as may be determined by him with the consent of the Minister for the Civil Service.
5Any expenses incurred by the Advisory Council with the approval of the Secretary of State shall be defrayed by the Secretary of State.
Section 2.
1The following substances and products, namely:—
| F1Acetorphine. | Lysergamide. |
| [F2Alfentanil.] | Lysergide and other N-alkyl derivatives of lysergamide. |
| Allylprodine. | Mescaline. |
| Alphacetylmethadol. | Metazocine. |
| Alphameprodine. | Methadone. |
| Alphamethadol. | Methadyl acetate. |
| Alphaprodine. | Methyldesorphine. |
| Anileridine. | Methyldihydromorphine (6-methyldihydromorphine). |
| Benzethidine. | Metopon. |
| Benzylmorphine (3-benzylmorphine). | Morpheridine. |
| Betacetylmethadol. | Morphine. |
| Betameprodine. | Morphine methobromide, morphine N-oxide and other pentavalent nitrogen morphine derivatives. |
| Betamethadol. | Myrophine. |
| Betaprodine. | . . . F3 |
| Bezitramide. | Nicomorphine (3,6-dinicotinoylmorphine). |
| Bufotenine. | Noracymethadol. |
| Cannabinol, except where contained in cannabis or cannabis resin. | Norlevorphanol. |
| Cannabinol derivatives. | Normethadone. |
| [F4Carfentanil.] | Normorphine. |
| Clonitazene. | Norpipanone. |
| Coca leaf. | Opium, whether raw, prepared or medicinal. |
| Cocaine. | Oxycodone. |
| Desomorphine. | Oxymorphone. |
| Dextromoramide. | Pethidine. |
| Diamorphine. | Phenadoxone. |
| Diampromide. | Phenampromide. |
| Diethylthiambutene. | Phenazocine. |
| [F5Difenoxin (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid).] | [F6Phencyclidine.] |
| Dihydrocodeinone O-carboxymethyloxime. | Phenomorphan. |
| Dihydromorphine. | Phenoperidine. |
| Dimenoxadole. | Piminodine. |
| Dimepheptanol. | Piritramide. |
| Dimethylthiambutene. | Poppy-straw and concentrate of poppy-straw. |
| Dioxaphetyl butyrate. | Proheptazine. |
| Diphenoxylate. | Properidine (1-methyl-4-phenyl-piperidine-4-carboxylic acid isopropyl ester). |
| Dipipanone. | Psilocin. |
| [F7Drotebanol (3,4-dimethoxy-17-methylmorphinan-6b, 14-diol).] | Racemethorphan. |
| Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine. | Racemoramide. |
| Ethylmethylthiambutene. | Racemorphan. |
| [F2Eticyclidine.] | [F2Rolicyclidine.] |
| Etonitazene. | [F8Sufentanil.] |
| Etorphine. | [F2Tenocylidine.] |
| Etoxeridine. | Thebacon. |
| [ F9Etryptamine] | |
| Fentanyl. | Thebaine. |
| Furethidine. | [F8Tilidate.] |
| Hydrocodone. | Trimeperidine. |
| Hydromorphinol. | [F104-Bromo-2,5-dimethoxy-a-methylphenethylamine]. |
| Hydromorphone. | 4-Cyano-2-dimethylamino-4,4-diphenylbutane. |
| Hydroxypethidine. | 4-Cyano-1-methyl-4-phenyl-piperidine. |
| Isomethadone. | N,N-Diethyltryptamine. |
| Ketobemidone. | N,N-Dimethyltryptamine. |
| Levomethorphan. | 2,5-Dimethoxy-a,4-dimethylphenethylamine. |
| Levomoramide. | [F11N-Hydroxy-tenamphetamine.] |
| Levophenacylmorphan. | 1-Methyl-4-phenylpiperidine-4-carboxylic acid. |
| Levorphanol. | 2-Methyl-3-morpholino-1, 1-diphenylpropanecarboxylic acid. |
| [F4Lofentanil] | [F124-Methyl-aminorex] |
| 4-Phenylpiperidine-4-carboxylic acid ethyl ester. | |
[F13(b)any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
(c)any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine anN-alkylphenethylamine,a-methylphenethylamine, anN-alkyl-a-methylphenethylamine,a-ethylphenethylamine, or anN-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents.]
[F14(d)any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from fentanyl by modification in any of the following ways, that is to say,
(i)by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
(ii)by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
(iii)by substitution in the piperidine ring with alkyl or alkenyl groups;
(iv)by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;
(v)by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;
(vi)by replacement of the N-propionyl group by another acyl group;
(e)any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from pethidine by modification in any of the following ways, that is to say,
(i)by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
(ii)by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
(iii)by substitution in the 4-phenyl ring wiith alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
(iv)by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;
(v)by formation of an N-oxide or of a quaternary base.]
F1
“(a)” inserted by S.I. 1977/1243, art. 3(a)
F2Word inserted by S.I. 1984/859, art. 2(2)
F3Words repealed by S.I. 1973/771, art. 2
F4Word inserted by S.I. 1986/2230, art. 2(2)(a)
F5Word inserted by S.I. 1975/421, art. 3
F6Word inserted by S.I. 1979/299, art. 2
F7Word inserted by S.I. 1973/771, art. 2
F8Word inserted by S.I. 1983/765, art. 2(a)
F9Sch. 2 Pt. I para. 1(a): Word inserted (1.5.1998) by S.I. 1998/750, art.2(2)
F10Words inserted by S.I. 1975/421, art. 3
F11Word inserted by S.I. 1990/2589, art. 2(a)(i)
F12Word inserted by S.I. 1990/2589, art. 2(a)(ii)
F13Sch. 2 para 1(b)(c) added by S.I. 1977/1243, art. 3(b)
F14Sch. 2 para. 1(d)(e) added by S.I. 1986/2230, art. 2(2)(b)
2Any stereoisomeric form of a substance for the time being specified in paragraph 1 above not being dextromethorphan or dextrorphan.
3Any ester or ether of a substance for the time being specified in paragraph 1 or 2 above [F1not being a substance for the time being specified in Part II of this Schedule].
4Any salt of a substance for the time being specified in any of paragraphs 1 to 3 above.
5Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 4 above.
6Any preparation designed for administration by injection which includes a substance or product for the time being specified in any of paragraphs 1 to 3 of Part II of this Schedule.
1The following substances and products, namely:—
| Acetyldihydrocodeine. | Methylamphetamine [F2a-Methylphenethylhydroxylamine;]. |
| Amphetamine. | Methylphenidate. |
| Cannabis and cannabis resin. | [F3Methylphenobarbitone.] |
| Codeine. | Nicocodine. |
| . . . F4 | [F5Nicodicodine (6-nicotinoyldihydrocodeine).] |
| Dihydrocodeine. | Norcodeine. |
| Ethylmorphine (3-ethylmorphine). | [F6Pentazocine.] |
| [F7Glutethimide.] | Phenmetrazine. |
| [F7Lefetamine.] | Pholcodine. |
| [F3Mecloqualone.] | [F8Propiram.] |
| [F3Methaqualone.] | [F9Zipeprol] |
| [F9Methcathinone] |
[F10(b)any 5,5 disubstituted barbituric acid.]
F1
“(a)” inserted by S.I. 1984/859, art. 2
F2Word in Sch. 2 Pt. II para. 1a inserted (1.2.2002) by S.I. 2001/3923, art. 2(3)
F3Word inserted by S.I. 1984/859, art. 2(3)
F4Word repealed by S.I. 1985/1995, art. 2(2)(a)
F5Words inserted by S.I. 1973/771, art. 2
F6Word inserted by S.I. 1985/1995, art. 2(2)(c)
F7Word inserted by S.I. 1985/1995, art. 2(2)(b)
F8Word inserted by S.I. 1973/771, art. 2
F9In Sch. 2 Pt. II para. 1(a): Word inserted (1.5.1998) by S.I. 1998/750, art. 2(3)(a),(b)
F10Sub-para. (b) added by S.I. 1984/859, art. 2(3)
2Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule.
3Any salt of a substance for the time being specified in paragraph 1 or 2 of this Part of this Schedule.
4Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule, not being a preparation falling within paragraph 6 of Part I of this Schedule.
1The following substances, namely:—
| [F2Alprazolam.] | [F2Lorazepam.] |
| [F3Aminorex] | |
| Benzphetamine. | [F2Lormetazepam.] |
| [F2Bromazepam.] | [F2Mazindol.] |
| [F3Brotizolam] | |
| [F4Buprenorphine] | [F2Medazepam.] |
| [F2Camazepam.] | [F5Mefenorex.] |
| [F5Cathine.] | . . . F6 |
| [F5Cathinone.] | Mephentermine. |
| [F2Chlordiazepoxide.] | [F2Meprobamate.] |
| [F3Mesocarb] | |
| Chlorphentermine. | . . . F7 |
| [F2Clobazam.] | [F2Methyprylone.] |
| [F2Clorazepic acid.] | [F8Midazolam.] |
| [F2Clonazepam.] | [F2Nimetazepam.] |
| [F2Clotiazepam.] | [F2Nitrazepam.] |
| [F2Cloxazolam.] | [F2Nordazepam.] |
| [F2Delorazepam.] | [F2Oxazepam.] |
| [F9Dextropropoxyphene.] | [F2Oxazolam.] |
| [F2Diazepam.] | [F10Pemoline.] |
| [F11Diethylpropion.] | . . . F6 |
| [F2Estazolam.] | Phendimetrazine. |
| [F2Ethchlorvynol.] | [F2Phentermine.] |
| [F2Ethinamate.] | [F2Pinazepam.] |
| [F2Ethyl loflazepate.] | . . . F6 |
| [F5Fencamfamin.] | Pipradrol. |
| [F5Fenethylline.] | [F2Prazepam.] |
| [F5Fenproporex.] | . . . F6 |
| [F2Fludiazepam.] | F12. . . |
| [F2Flunitrazepam.] | [F5Pyrovalerone.] |
| [F2Flurazepam.] | [F2Temazepam.] |
| [F2Halazepam.] | [F2Tetrazepam.] |
| [F2Haloxazolam.] | [F2Triazolam.] |
| [F2Ketazolam.] | [F5N-Ethylamphetamine. ] |
| [F2Loprazolam.] |
[F13(b)
Atamestane.
Bolandiol.
Bolasterone.
Bolazine.
Boldenone.
Bolenol.
Bolmantalate.
Calusterone.
4-Chloromethandienone.
Clostebol.
Drostanolone.
Enestebol.
Epitiostanol.
Ethyloestrenol.
Fluoxymesterone.
Formebolone.
Furazabol.
Mebolazine.
Mepitiostane.
Mesabolone.
Mestanolone.
Mesterolone.
Methandienone.
Methandriol.
Methenolone.
Methyltestosterone.
Metribolone.
Mibolerone.
Nandrolone.
Norboletone.
Norclostebol.
Norethandrolone.
Ovandrotone.
Oxabolone.
Oxandrolone.
Oxymesterone.
Oxymetholone.
Prasterone.
Propetandrol.
Quinbolone.
Roxibolone.
Silandrone.
Stanolone.
Stanozolol.
Stenbolone.
Testosterone.
Thiomesterone.
Trenbolone.
(c)any compound (not being Trilostane or a compound for the time being specified in sub-paragraph (b) above) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say,
(i)by further substitution at position 17 by a methyl or ethyl group;
(ii)by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
(iii)by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
(iv)by fusion of ring A with a heterocyclic system;
(d)any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in sub-paragraph (b) or described in sub-paragraph (c) above;
(e)
Chorionic Gonadotrophin (HCG).
Clenbuterol.
Non-human chorionic gonadotrophin.
Somatotropin.
Somatrem.
Somatropin.]
F1In Sch. 2 Pt. III para. 1, sub-para. (a) inserted (1.9.1996) by S.I. 1996/1300, art. 2(2)(a)
F2Word inserted by S.I. 1985/1995, art. 2(3)
F3In Sch. 2 Pt. III para. 1(a) word inserted (1.5.1998) by S.I. 1998/750, art. 2(1)(4)(a)(b)(c)
F4Word inserted by S.I. 1989/1340, art. 2(a)
F5Word inserted by S.I. 1986/2230, art. 2(3)
F6Words repealed by S.I. 1973/771, art. 2
F7Word repealed by S.I. 1984/859, art. 2(4)(a)
F8Word inserted by S.I. 1990/2589, art. 2(b)
F9Word inserted by S.I. 1983/765, art. 2(a)
F10Word inserted by S.I. 1989/1340, art. 2(b)
F11Word inserted by S.I. 1984/859, art. 2(4)(a)
F12Word in Sch. 2 para.1 omitted (1.9.1995) by virtue of S.I. 1995/1966, art. 2
F13In Sch. 2 Pt. III para. 1, sub-para. (b) to sub-para. (e) added (1.9.1996) by S.I. 1996/1300, art. 2(2)(b)
2Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule [F1not being phenylpropanolamine.]
3Any salt of a substance for the time being specified in paragraph 1 or 2 of this Part of this Schedule.
4Any preparation or other product containing a substance for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule.
Misuse of Drugs Act 1971